Why You’re Paying More to Breathe

How Big Pharma claimed the ecofriendly high ground while sucking billions of dollars out of asthma sufferers.

Illustration: Alison Seiffer

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.


If you or someone you know has asthma, you’ve probably noticed that the price of inhalers has jumped—from as little as $5 a few years ago to as much as $60 today. How’d that happen? The answer is a case study in how drug companies turned a well-meaning environmental regulation into an opportunity to suck billions from consumers.

PHARMA’S BIG PROBLEM In 1987, as part of an international treaty known as the Montreal Protocol, 26 nations agreed to phase out ozone-depleting chlorofluorocarbons. That could have been bad news for pharmaceutical manufacturers, which used CFCs as propellants in their asthma inhalers.

THE BRILLIANT SOLUTION Yet pharmaceutical companies, worried about the emergence of generic competition, soon spied an opening. If they could create and patent a new variety of CFC-free inhalers, securing the exclusive rights to sell them, they could force off-brand competitors out of the market and jack up prices. In 1989, Glaxo Wellcome and seven other (PDF) pharmaceutical firms formed the International Pharmaceutical Aerosol Consortium (IPAC) to come up with a new ozone-friendly product. By 1997, the first CFC-free inhalers hit pharmacy shelves.

PHARMA’S NEXT BIG PROBLEM The drug companies claimed to have spent more than $1 billion on this transition, so they weren’t happy when scientists raised concerns about hydrofluorocarbons (HFCs), the group of gases used in the new inhalers. These propellants don’t harm the ozone layer, but they are powerful greenhouse gases that contribute to climate change. In light of this, several researchers and one generic drug company argued that phasing out the old CFC-based inhalers didn’t make environmental sense—especially given the higher prices asthma patients would have to pay for their medicine.

THE NEXT BRILLIANT SOLUTION But not to worry: The pharma consortium transformed from primarily an R&D outfit searching for substitutes for CFC-based inhalers into a lobbying group intent on eliminating the old inhalers. It set up shop in the K Street offices of Drinker Biddle, a major DC law firm. Between 2005 and 2010, it spent $520,000 on lobbying. (It probably spent even more; as a trade group, it’s not required to disclose all of its advocacy spending.) Meanwhile, IPAC lobbied for other countries to enact similar bans, arguing that CFC-based inhalers should be eliminated for environmental reasons and replaced with the new, HFC-based inhalers.

The lobbying paid off. In 2005, the Food and Drug Administration (FDA) approved an outright ban on many CFC-based inhalers starting in 2009 (PDF). This June, the agency’s ban on Aerobid, an inhaler used for acute asthma, took effect. Combivent, another popular treatment, will be phased out by the end of 2013.

THE FINANCIAL PAYOFF Many of the patents for the new inhalers won’t expire for another six years, so there likely won’t be any generics until then, unless the patents are challenged in court. The switch to the new inhalers will cost American consumers, insurance companies, and the government some $8 billion by 2017, according to FDA estimates. That’s money in the drug companies’ pockets. In 2007, a top market-research firm alerted investors that the US inhaler market “will soon change from low-value to significant.” Sure enough, at nearly $1 billion a year, sales of the market-leading inhaler, ProAir, now rival Viagra’s.

THE ENVIRONMENTAL PAYOFF Oh right, that. By upgrading their inhalers, Americans will prevent about 1,300 tons of CFC emissions a year. By comparison, the estimated global CFC emissions between 1986 and 2010 were 8.3 million tons. According to the University of Michigan’s Edward Parson, an expert on ozone regulations, this impact will be “tiny.”

One estimate suggests that CFC-free inhalers will accelerate the repair of the ozone layer by just a matter of days. And of course, the industry has solved its ozone problem but still has a climate-change problem. “It’s just absurd to think that this is anything that could have a measurable impact,” says Dean Baker of the Center for Economic and Policy Research. “You’d be hard-pressed to find a law that raised costs so much for such a nonexistent benefit to the environment.”

AN IMPORTANT UPDATE

We’re falling behind our online fundraising goals and we can’t sustain coming up short on donations month after month. Perhaps you’ve heard? It is impossibly hard in the news business right now, with layoffs intensifying and fancy new startups and funding going kaput.

The crisis facing journalism and democracy isn’t going away anytime soon. And neither is Mother Jones, our readers, or our unique way of doing in-depth reporting that exists to bring about change.

Which is exactly why, despite the challenges we face, we just took a big gulp and joined forces with the Center for Investigative Reporting, a team of ace journalists who create the amazing podcast and public radio show Reveal.

If you can part with even just a few bucks, please help us pick up the pace of donations. We simply can’t afford to keep falling behind on our fundraising targets month after month.

Editor-in-Chief Clara Jeffery said it well to our team recently, and that team 100 percent includes readers like you who make it all possible: “This is a year to prove that we can pull off this merger, grow our audiences and impact, attract more funding and keep growing. More broadly, it’s a year when the very future of both journalism and democracy is on the line. We have to go for every important story, every reader/listener/viewer, and leave it all on the field. I’m very proud of all the hard work that’s gotten us to this moment, and confident that we can meet it.”

Let’s do this. If you can right now, please support Mother Jones and investigative journalism with an urgently needed donation today.

payment methods

AN IMPORTANT UPDATE

We’re falling behind our online fundraising goals and we can’t sustain coming up short on donations month after month. Perhaps you’ve heard? It is impossibly hard in the news business right now, with layoffs intensifying and fancy new startups and funding going kaput.

The crisis facing journalism and democracy isn’t going away anytime soon. And neither is Mother Jones, our readers, or our unique way of doing in-depth reporting that exists to bring about change.

Which is exactly why, despite the challenges we face, we just took a big gulp and joined forces with the Center for Investigative Reporting, a team of ace journalists who create the amazing podcast and public radio show Reveal.

If you can part with even just a few bucks, please help us pick up the pace of donations. We simply can’t afford to keep falling behind on our fundraising targets month after month.

Editor-in-Chief Clara Jeffery said it well to our team recently, and that team 100 percent includes readers like you who make it all possible: “This is a year to prove that we can pull off this merger, grow our audiences and impact, attract more funding and keep growing. More broadly, it’s a year when the very future of both journalism and democracy is on the line. We have to go for every important story, every reader/listener/viewer, and leave it all on the field. I’m very proud of all the hard work that’s gotten us to this moment, and confident that we can meet it.”

Let’s do this. If you can right now, please support Mother Jones and investigative journalism with an urgently needed donation today.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate